Located near the Gare de Nord in Paris is France’s main open drug scene.
The number of drugs picking up a designation from regulators — first treatments or speciality drugs — across the European Union, the US, and Japan have risen by 117 percent in 10 years.
The FDA has been on the right track when taking forward promising pipeline drugs for expedited new drug application (NDA) review.
The US states of New Hampshire and South Carolina are suing Purdue Pharma, the manufacturer of OxyContin for its role in the opioid crisis.
A Marks and Spencer caught some heat last week for installing a high-pitched alarm to deter people from sleeping around its premises.
A breakthrough in migraine treatment is expected to create a $5bn dollar industry and improve the lives of millions of sufferers worldwide.
Heart surgery, prenatal care, organ transplants, and blood transfusions.
The Liberal Democrat manifesto will offer the British public a chance to reverse Brexit.
Some of the world’s biggest drug companies warned that they will withdraw from the UK market if the NHS does not receive an extra £20bn a year.
US president Donald Trump’s insistence that manufacturing move back to the US has sparked a wave of promises from big biopharma firms over the sector’s future.
Global pharmaceutical stock indices rose by up to 12 percent after Donald Trump’s US election victory in November.
When it comes to clinical trials, sometimes the results aren’t completely clear.
Given the scarcity of commercially-ready oncology assets, cancer drugs are appealing to big pharma with lots of cash and high prices are being paid for hopeful products.